Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 729 | 91 | 629 |
| Samples | 338 | 56 | 276 |
| Peptides | 262 | 33 | 242 |
Function
CCNA1 · Cyclin A1
The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. The cyclin encoded by this gene was shown to be expressed in testis and brain, as well as in several leukemic cell lines, and is thought to primarily function in the control of the germline meiotic cell cycle. This cyclin binds both CDK2 and CDC2 kinases, which give two distinct kinase activities, one appearing in S phase, the other in G2, and thus regulate separate functions in cell cycle. This cyclin was found to bind to important cell cycle regulators, such as Rb family proteins, transcription factor E2F-1, and the p21 family proteins. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 234 amino-acid changes on canonical ENST00000630422 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CCNA1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CCNA1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 9/210 4% | 44/1899 2% |
| Endometrial Carcinoma | 1/42 2% | 12/612 2% |
| Non-Small Cell Lung Carcinoma | 14/304 5% | 15/1390 1% |
| Colorectal Carcinoma | 5/143 4% | 40/3239 1% |
| Gastric Carcinoma | 2/74 3% | 21/1809 1% |
| Other Solid Cancers | 0/94 0% | 18/1515 1% |
| Neuroendocrine Tumour | 6/154 4% | 2/577 0% |
| Hepatocellular Carcinoma | 0/46 0% | 23/2210 1% |
| Ovarian Carcinoma | 0/109 0% | 10/998 1% |
| Bladder Carcinoma | 0/58 0% | 9/956 1% |
| Plasma Cell Myeloma | 2/44 5% | 1/305 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 11/1592 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Esophageal Carcinoma | 0/23 0% | 6/769 1% |
| Other Sarcomas | 0/69 0% | 5/699 1% |
| Head and Neck Carcinoma | 2/85 2% | 7/1574 0% |
| Biliary Tract Carcinoma | 1/54 2% | 4/950 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Breast Carcinoma | 3/144 2% | 11/3264 0% |
| Non-Cancerous | 2/104 2% | 1/830 0% |
| Glioma | 0/52 0% | 7/2127 0% |
| Other Blood Cancers | 1/61 2% | 7/2725 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 5/2534 0% |
| Kidney Carcinoma | 0/85 0% | 5/1862 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 4/2550 0% |
| B-Lymphoblastic Leukemia | 3/55 5% | 0/2640 0% |
| Prostate Carcinoma | 0/13 0% | 2/2105 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
Mutation Distribution
Where CCNA1 is mutated · all tissues, split by cell line vs tissue
How many mutations in CCNA1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 729 mutations in CCNA1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|